טראמפ חתם על הצו המאפשר הנגשה של טיפולים בסמים פסיכדליים

President Trump signing a new executive order aimed at fast-tracking access to psychedelic drug treatments for mental health conditions especially among veterans. NDD's Daniel Monaghan spoke with an addiction specialist for analysis on that. With many other veterans. President Trump says the move could help address what he calls a national crisis pointing to high suicide rates among veterans. In many cases these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression including our cherished veterans. Our veterans are having a tremendous. The order directs federal agencies to accelerate research and clinical trials for substances like psilocybin, MDMA and ibogaine. Drugs currently restricted under the Controlled Substances Act. Master Certified Addiction Professional John Pulse says there's a lot of promise in the treatments especially for PTSD addiction and depression. But the reality is is we're still really early in the science and the key is making sure that we go slow and that's safe controlled and done in a more of an evidence-based way. Pulse discussing ibogaine. Which is a plant-based psychedelic you know that can last for you know anywhere from like 12 to 16 hours in a pretty intense intense psychedelic trip. And the mechanism is thought to really resolve more severe and pervasive issues in a short period of time. Pulse says psilocybin a chemical found in certain mushrooms and MDMA commonly known as ecstasy should be used in the format of psychedelic assisted therapy. Right so it's meant to essentially accelerate and remove some of the things that are blocking the person off. And it's also very effective in what I would call treatment resistant depression PTSD addiction issues where people aren't responding very well to conventional methods. The addiction specialist emphasizes that treatment with psychedelics is a two-part process. There's some of the initial insight you can develop from the psychedelic experience but then there's the integration piece which I think is what you're talking about there. And that integration can look like intensive psychotherapy, trauma therapy, community-based reintegration and purpose. He MDMA assisted psychotherapy somebody will actually sit down with the psychotherapist for hours at a time and have fluid conversations where you know their their ego is not really getting in the way of them processing difficult issues. They're able to talk about things without being severely triggered. So because it produces that euphoria it allows them to process through some otherwise traumatic events that they may not have talked about. Pulse says bad trips can be dangerous for some patients. However there are plenty of people who will have a bad trip and maybe they have a pre-existing bipolar disorder or an underlying psychotic disorder such as schizophrenia or schizoaffective disorder that can really impact the person's ability to reintegrate and come back to a baseline. The addiction specialist says he's never met anyone during his nearly 15 years of practice who was solely addicted to psychedelics. But again I think it's important to remember is that we are so early on in this type of research and I think the funding being allocated is a good thing and something called the right to try meaning a patient's right to try this if they haven't responded to other methods is good. Pulse warns that these types of psychedelics are not without harm or risk. Daniel Monaghan, NTD News.